your timeline and today's announcement both say Q3 2024 for a Phase 1b readout. If they were running behind there, I would expect them to have outlined a revised timeline for the readout in today's update. But they haven't? In any case, a 1 quarter slip is not a big deal for me.
On Checkvacc, we all know this was deprioritised and now the MAST study is recruiting breast cancer patients. That makes more sense to me. Outside of doing it for Yuman, I'm still not clear as to why we wanted to actually run 2 CF33 trials in parallel?
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-69
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $490.4M | |||
| Open | High | Low | Value | Volume |
| 6.8¢ | 6.9¢ | 6.6¢ | $647.9K | 9.625M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 309078 | 6.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.8¢ | 759722 | 11 |
View Market Depth
| Last trade - 16.10pm 31/05/2024 (20 minute delay) ? |
|
|||||
|
Last
6.7¢ |
Change
0.000 ( 0.15 %) |
||||
| Open | High | Low | Volume | ||
| 6.8¢ | 6.9¢ | 6.6¢ | 3602017 | ||
| Last updated 15.57pm 31/05/2024 ? | |||||
| IMU (ASX) Chart |